The Future of Crystallography in Drug Discovery
Overview
Pharmacology
Affiliations
Introduction: X-ray crystallography plays an important role in structure-based drug design (SBDD), and accurate analysis of crystal structures of target macromolecules and macromolecule-ligand complexes is critical at all stages. However, whereas there has been significant progress in improving methods of structural biology, particularly in X-ray crystallography, corresponding progress in the development of computational methods (such as in silico high-throughput screening) is still on the horizon. Crystal structures can be overinterpreted and thus bias hypotheses and follow-up experiments. As in any experimental science, the models of macromolecular structures derived from X-ray diffraction data have their limitations, which need to be critically evaluated and well understood for structure-based drug discovery.
Areas Covered: This review describes how the validity, accuracy and precision of a protein or nucleic acid structure determined by X-ray crystallography can be evaluated from three different perspectives: i) the nature of the diffraction experiment; ii) the interpretation of an electron density map; and iii) the interpretation of the structural model in terms of function and mechanism. The strategies to optimally exploit a macromolecular structure are also discussed in the context of 'Big Data' analysis, biochemical experimental design and structure-based drug discovery.
Expert Opinion: Although X-ray crystallography is one of the most detailed 'microscopes' available today for examining macromolecular structures, the authors would like to re-emphasize that such structures are only simplified models of the target macromolecules. The authors also wish to reinforce the idea that a structure should not be thought of as a set of precise coordinates but rather as a framework for generating hypotheses to be explored. Numerous biochemical and biophysical experiments, including new diffraction experiments, can and should be performed to verify or falsify these hypotheses. X-ray crystallography will find its future application in drug discovery by the development of specific tools that would allow realistic interpretation of the outcome coordinates and/or support testing of these hypotheses.
Fadini A, Li M, McCoy A, Terwilliger T, Read R, Hekstra D bioRxiv. 2025; .
PMID: 40027838 PMC: 11870471. DOI: 10.1101/2025.02.18.638828.
CheckMyMetal (CMM): validating metal-binding sites in X-ray and cryo-EM data.
Gucwa M, Bijak V, Zheng H, Murzyn K, Minor W IUCrJ. 2024; 11(Pt 5):871-877.
PMID: 39141478 PMC: 11364027. DOI: 10.1107/S2052252524007073.
Yang Y, Ahmad E, Premkumar V, Liu A, Ashikur Rahman S, Nikolovska-Coleska Z Protein Sci. 2024; 33(6):e5019.
PMID: 38747396 PMC: 11094776. DOI: 10.1002/pro.5019.
Continuous Validation Across Macromolecular Structure Determination Process.
Bijak V, Gucwa M, Lenkiewicz J, Murzyn K, Cooper D, Minor W Nihon Kesshō Gakkaishi. 2023; 65(1):10-16.
PMID: 37416056 PMC: 10321142. DOI: 10.5940/jcrsj.65.10.
CMM-An enhanced platform for interactive validation of metal binding sites.
Gucwa M, Lenkiewicz J, Zheng H, Cymborowski M, Cooper D, Murzyn K Protein Sci. 2022; 32(1):e4525.
PMID: 36464767 PMC: 9794025. DOI: 10.1002/pro.4525.